Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pituitary Neoplasms | 53 | 2024 | 1322 | 7.740 |
Why?
|
Adenoma | 48 | 2024 | 2155 | 5.660 |
Why?
|
Pituitary ACTH Hypersecretion | 15 | 2024 | 181 | 3.030 |
Why?
|
Acromegaly | 14 | 2024 | 316 | 2.640 |
Why?
|
ACTH-Secreting Pituitary Adenoma | 10 | 2023 | 64 | 2.530 |
Why?
|
Radiosurgery | 18 | 2024 | 1328 | 2.520 |
Why?
|
Craniopharyngioma | 9 | 2023 | 276 | 2.510 |
Why?
|
Hypopituitarism | 8 | 2022 | 253 | 2.110 |
Why?
|
Somatostatin | 6 | 2020 | 459 | 1.750 |
Why?
|
Thyrotropin | 4 | 2024 | 835 | 1.200 |
Why?
|
Neurosurgical Procedures | 12 | 2021 | 2077 | 1.040 |
Why?
|
Growth Hormone-Secreting Pituitary Adenoma | 6 | 2024 | 49 | 0.960 |
Why?
|
Human Growth Hormone | 9 | 2024 | 639 | 0.950 |
Why?
|
Serum Amyloid A Protein | 1 | 2024 | 127 | 0.910 |
Why?
|
Adrenocorticotropic Hormone | 10 | 2024 | 618 | 0.890 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2024 | 164 | 0.830 |
Why?
|
Hypothalamus | 3 | 2023 | 995 | 0.740 |
Why?
|
Endosomal Sorting Complexes Required for Transport | 2 | 2019 | 146 | 0.720 |
Why?
|
Neoplasm Recurrence, Local | 13 | 2023 | 9372 | 0.710 |
Why?
|
Microsurgery | 4 | 2021 | 798 | 0.680 |
Why?
|
Pro-Opiomelanocortin | 5 | 2024 | 139 | 0.660 |
Why?
|
Octreotide | 1 | 2020 | 157 | 0.660 |
Why?
|
Inflammasomes | 1 | 2024 | 544 | 0.640 |
Why?
|
Prolactinoma | 5 | 2023 | 114 | 0.630 |
Why?
|
Ubiquitin Thiolesterase | 2 | 2019 | 455 | 0.620 |
Why?
|
Third Ventricle | 2 | 2016 | 78 | 0.600 |
Why?
|
Endopeptidases | 2 | 2019 | 759 | 0.600 |
Why?
|
Peptides, Cyclic | 1 | 2020 | 390 | 0.600 |
Why?
|
Infratentorial Neoplasms | 1 | 2019 | 94 | 0.590 |
Why?
|
Pituitary Gland | 9 | 2023 | 633 | 0.570 |
Why?
|
Ovarian Hyperstimulation Syndrome | 1 | 2017 | 46 | 0.560 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2016 | 43 | 0.540 |
Why?
|
Receptors, Somatostatin | 4 | 2024 | 138 | 0.540 |
Why?
|
Follicle Stimulating Hormone | 2 | 2017 | 731 | 0.530 |
Why?
|
Amyloidosis | 1 | 2024 | 884 | 0.530 |
Why?
|
Prion Diseases | 3 | 2022 | 99 | 0.520 |
Why?
|
Prions | 3 | 2022 | 177 | 0.510 |
Why?
|
Ependymoma | 1 | 2019 | 310 | 0.510 |
Why?
|
Skull Base Neoplasms | 3 | 2018 | 276 | 0.500 |
Why?
|
Insulin-Like Growth Factor I | 4 | 2022 | 1936 | 0.490 |
Why?
|
Pituitary Hormones | 2 | 2013 | 183 | 0.420 |
Why?
|
Meningioma | 4 | 2020 | 1222 | 0.400 |
Why?
|
Treatment Outcome | 34 | 2024 | 65223 | 0.390 |
Why?
|
Cushing Syndrome | 4 | 2022 | 241 | 0.390 |
Why?
|
Zygoma | 1 | 2012 | 52 | 0.390 |
Why?
|
Frontal Bone | 1 | 2012 | 105 | 0.380 |
Why?
|
Hypophysectomy | 3 | 2020 | 113 | 0.360 |
Why?
|
Neoplasm, Residual | 4 | 2019 | 1009 | 0.330 |
Why?
|
Deamino Arginine Vasopressin | 1 | 2009 | 87 | 0.320 |
Why?
|
Retrospective Studies | 28 | 2024 | 81505 | 0.320 |
Why?
|
Optic Nerve Diseases | 2 | 2012 | 342 | 0.310 |
Why?
|
Incidental Findings | 1 | 2013 | 696 | 0.310 |
Why?
|
Orbit | 1 | 2012 | 458 | 0.300 |
Why?
|
Adult | 48 | 2024 | 223055 | 0.290 |
Why?
|
Sphenoid Bone | 4 | 2021 | 176 | 0.290 |
Why?
|
Receptors, Glucocorticoid | 2 | 2023 | 308 | 0.290 |
Why?
|
Anesthesia | 1 | 2019 | 1581 | 0.290 |
Why?
|
Humans | 94 | 2024 | 765823 | 0.290 |
Why?
|
Dacarbazine | 1 | 2010 | 552 | 0.290 |
Why?
|
Ligands | 4 | 2024 | 3273 | 0.290 |
Why?
|
Hormones | 3 | 2023 | 864 | 0.280 |
Why?
|
Decompression, Surgical | 2 | 2012 | 602 | 0.280 |
Why?
|
Temporal Bone | 1 | 2012 | 683 | 0.280 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2010 | 614 | 0.270 |
Why?
|
Spinal Fractures | 2 | 2024 | 703 | 0.270 |
Why?
|
Cranial Irradiation | 4 | 2020 | 384 | 0.270 |
Why?
|
Female | 58 | 2024 | 396050 | 0.250 |
Why?
|
Combined Modality Therapy | 6 | 2021 | 8529 | 0.250 |
Why?
|
Dopamine Agonists | 3 | 2023 | 346 | 0.240 |
Why?
|
Middle Aged | 42 | 2024 | 223016 | 0.240 |
Why?
|
Pituitary Gland, Posterior | 2 | 2016 | 41 | 0.240 |
Why?
|
Male | 55 | 2024 | 363740 | 0.240 |
Why?
|
Prolactin | 3 | 2023 | 625 | 0.240 |
Why?
|
Granular Cell Tumor | 2 | 2016 | 46 | 0.230 |
Why?
|
Hydrocortisone | 6 | 2022 | 1832 | 0.230 |
Why?
|
Vision Disorders | 5 | 2018 | 1087 | 0.230 |
Why?
|
Chordoma | 2 | 2020 | 343 | 0.220 |
Why?
|
Salvage Therapy | 1 | 2010 | 1272 | 0.220 |
Why?
|
Postoperative Period | 4 | 2016 | 1817 | 0.210 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2023 | 59 | 0.210 |
Why?
|
PrPC Proteins | 1 | 2022 | 35 | 0.200 |
Why?
|
Italy | 2 | 2015 | 851 | 0.200 |
Why?
|
Calreticulin | 1 | 2022 | 111 | 0.190 |
Why?
|
Sphenoid Sinus | 2 | 2016 | 101 | 0.190 |
Why?
|
Thyroid Neoplasms | 1 | 2015 | 2354 | 0.190 |
Why?
|
Nelson Syndrome | 1 | 2021 | 20 | 0.180 |
Why?
|
Visual Pathways | 3 | 2024 | 556 | 0.180 |
Why?
|
Sella Turcica | 1 | 2021 | 117 | 0.180 |
Why?
|
Receptors, Somatotropin | 1 | 2020 | 58 | 0.170 |
Why?
|
Antineoplastic Agents | 2 | 2023 | 13635 | 0.170 |
Why?
|
Follow-Up Studies | 11 | 2024 | 39226 | 0.170 |
Why?
|
Dexamethasone | 3 | 2023 | 1963 | 0.170 |
Why?
|
Neuronavigation | 1 | 2021 | 170 | 0.170 |
Why?
|
Craniotomy | 3 | 2021 | 731 | 0.170 |
Why?
|
Prognosis | 6 | 2020 | 29915 | 0.170 |
Why?
|
Luteinizing Hormone | 2 | 2017 | 826 | 0.170 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2021 | 193 | 0.170 |
Why?
|
Optic Chiasm | 2 | 2018 | 89 | 0.170 |
Why?
|
Organs at Risk | 1 | 2021 | 352 | 0.160 |
Why?
|
Aged | 23 | 2024 | 171178 | 0.160 |
Why?
|
History, 19th Century | 1 | 2021 | 711 | 0.160 |
Why?
|
Oxytocin | 1 | 2023 | 404 | 0.160 |
Why?
|
Propensity Score | 2 | 2024 | 1967 | 0.160 |
Why?
|
Fluorescence | 1 | 2021 | 753 | 0.160 |
Why?
|
Young Adult | 12 | 2023 | 59849 | 0.160 |
Why?
|
Magnetic Resonance Imaging | 14 | 2023 | 36542 | 0.160 |
Why?
|
Adrenalectomy | 1 | 2021 | 344 | 0.160 |
Why?
|
Calculi | 1 | 2019 | 48 | 0.150 |
Why?
|
Watchful Waiting | 1 | 2023 | 493 | 0.150 |
Why?
|
Body Mass Index | 1 | 2016 | 13041 | 0.150 |
Why?
|
Empty Sella Syndrome | 1 | 2018 | 14 | 0.150 |
Why?
|
Gene Silencing | 1 | 2024 | 1505 | 0.150 |
Why?
|
Encephalocele | 1 | 2019 | 135 | 0.140 |
Why?
|
Chondrosarcoma | 1 | 2020 | 301 | 0.140 |
Why?
|
Cell Differentiation | 1 | 2015 | 11643 | 0.140 |
Why?
|
Myeloproliferative Disorders | 1 | 2022 | 615 | 0.130 |
Why?
|
Quality of Life | 6 | 2023 | 13466 | 0.130 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 452 | 0.130 |
Why?
|
Postoperative Complications | 10 | 2023 | 15794 | 0.130 |
Why?
|
Receptors, Corticotropin-Releasing Hormone | 1 | 2016 | 88 | 0.130 |
Why?
|
Autoantigens | 1 | 2020 | 883 | 0.130 |
Why?
|
Cerebellum | 2 | 2022 | 1519 | 0.120 |
Why?
|
Osteoporosis | 1 | 2024 | 1582 | 0.120 |
Why?
|
Ubiquitination | 1 | 2019 | 996 | 0.120 |
Why?
|
Bone Density | 2 | 2024 | 3490 | 0.120 |
Why?
|
Hypothyroidism | 3 | 2016 | 665 | 0.120 |
Why?
|
Meningeal Neoplasms | 2 | 2020 | 1253 | 0.120 |
Why?
|
Vision, Ocular | 1 | 2018 | 457 | 0.120 |
Why?
|
Hormone Replacement Therapy | 1 | 2020 | 752 | 0.120 |
Why?
|
alpha-Synuclein | 1 | 2021 | 771 | 0.120 |
Why?
|
Thyroid Function Tests | 1 | 2015 | 289 | 0.110 |
Why?
|
Bone and Bones | 1 | 2024 | 2555 | 0.110 |
Why?
|
Cerebellar Neoplasms | 1 | 2019 | 571 | 0.110 |
Why?
|
Corticotropin-Releasing Hormone | 4 | 2022 | 362 | 0.110 |
Why?
|
Cell Communication | 1 | 2021 | 1660 | 0.110 |
Why?
|
Reoperation | 4 | 2023 | 4309 | 0.110 |
Why?
|
Medulloblastoma | 1 | 2019 | 657 | 0.110 |
Why?
|
Consensus | 2 | 2020 | 3199 | 0.110 |
Why?
|
Radiotherapy | 1 | 2020 | 1493 | 0.110 |
Why?
|
History, 20th Century | 1 | 2021 | 2761 | 0.110 |
Why?
|
Premenopause | 1 | 2017 | 1039 | 0.110 |
Why?
|
Ultrasonography, Interventional | 1 | 2021 | 1532 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7416 | 0.100 |
Why?
|
Cranial Fossa, Posterior | 1 | 2013 | 134 | 0.100 |
Why?
|
Adolescent | 13 | 2023 | 88794 | 0.100 |
Why?
|
Plasmacytoma | 1 | 2013 | 174 | 0.100 |
Why?
|
Azacitidine | 1 | 2014 | 334 | 0.100 |
Why?
|
Enzyme Activators | 1 | 2012 | 56 | 0.100 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2016 | 1778 | 0.100 |
Why?
|
Monitoring, Intraoperative | 1 | 2019 | 939 | 0.100 |
Why?
|
Aminoimidazole Carboxamide | 1 | 2012 | 85 | 0.100 |
Why?
|
Ribonucleotides | 1 | 2012 | 114 | 0.100 |
Why?
|
Adenylate Kinase | 1 | 2012 | 100 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2021 | 2878 | 0.100 |
Why?
|
Genome, Human | 1 | 2024 | 4445 | 0.090 |
Why?
|
Adrenal Insufficiency | 1 | 2013 | 194 | 0.090 |
Why?
|
Preoperative Care | 1 | 2020 | 2244 | 0.090 |
Why?
|
Time Factors | 8 | 2020 | 40109 | 0.090 |
Why?
|
Vision Tests | 1 | 2012 | 159 | 0.090 |
Why?
|
Autoantibodies | 1 | 2020 | 2112 | 0.090 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2010 | 82 | 0.090 |
Why?
|
Recombinant Proteins | 1 | 2020 | 6489 | 0.090 |
Why?
|
Dura Mater | 1 | 2012 | 295 | 0.080 |
Why?
|
Patient Care Team | 1 | 2020 | 2513 | 0.080 |
Why?
|
Mice, Knockout | 1 | 2024 | 14445 | 0.080 |
Why?
|
Hyperprolactinemia | 2 | 2016 | 122 | 0.080 |
Why?
|
Disease-Free Survival | 3 | 2016 | 6839 | 0.080 |
Why?
|
Child | 9 | 2023 | 80509 | 0.080 |
Why?
|
Case-Control Studies | 4 | 2020 | 22227 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3614 | 0.070 |
Why?
|
Pediatrics | 1 | 2023 | 3602 | 0.070 |
Why?
|
Hypogonadism | 1 | 2013 | 801 | 0.070 |
Why?
|
Analysis of Variance | 2 | 2013 | 6204 | 0.070 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2011 | 701 | 0.070 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2010 | 588 | 0.070 |
Why?
|
Ergolines | 1 | 2006 | 55 | 0.060 |
Why?
|
Optic Nerve | 1 | 2009 | 568 | 0.060 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22323 | 0.060 |
Why?
|
Endothelin-1 | 1 | 2007 | 295 | 0.060 |
Why?
|
Prospective Studies | 5 | 2023 | 54798 | 0.060 |
Why?
|
Aged, 80 and over | 5 | 2021 | 59506 | 0.060 |
Why?
|
Cell Proliferation | 3 | 2017 | 10428 | 0.060 |
Why?
|
Magnetic Resonance Angiography | 1 | 2012 | 1430 | 0.060 |
Why?
|
Disease Models, Animal | 1 | 2024 | 18289 | 0.060 |
Why?
|
Tumor Cells, Cultured | 3 | 2019 | 6110 | 0.060 |
Why?
|
Clinical Competence | 1 | 2020 | 4860 | 0.060 |
Why?
|
Brain Neoplasms | 2 | 2020 | 9069 | 0.060 |
Why?
|
Visual Fields | 1 | 2011 | 1062 | 0.060 |
Why?
|
Remission Induction | 1 | 2010 | 2410 | 0.060 |
Why?
|
Inflammation | 1 | 2024 | 10845 | 0.060 |
Why?
|
Cohort Studies | 3 | 2024 | 41643 | 0.060 |
Why?
|
Mice | 4 | 2024 | 81788 | 0.060 |
Why?
|
Recurrence | 2 | 2009 | 8506 | 0.050 |
Why?
|
Obesity | 2 | 2023 | 13078 | 0.050 |
Why?
|
Intracranial Hypertension | 1 | 2006 | 190 | 0.050 |
Why?
|
Antibodies | 2 | 2022 | 2415 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6508 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8601 | 0.050 |
Why?
|
Visual Acuity | 1 | 2012 | 2672 | 0.050 |
Why?
|
Gene Library | 1 | 2024 | 1066 | 0.050 |
Why?
|
Animals | 6 | 2024 | 168730 | 0.050 |
Why?
|
HMGA2 Protein | 1 | 2002 | 101 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12800 | 0.050 |
Why?
|
Proportional Hazards Models | 2 | 2013 | 12520 | 0.050 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6545 | 0.050 |
Why?
|
Odds Ratio | 1 | 2013 | 9653 | 0.050 |
Why?
|
Anesthesia Recovery Period | 1 | 2002 | 155 | 0.050 |
Why?
|
Thyroid Hormones | 1 | 2004 | 409 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2007 | 3539 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 30188 | 0.040 |
Why?
|
Insulin | 2 | 2007 | 6601 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12056 | 0.040 |
Why?
|
Ribonucleoproteins | 1 | 2022 | 359 | 0.040 |
Why?
|
Sheep | 1 | 2022 | 1440 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2012 | 868 | 0.040 |
Why?
|
Thoracic Vertebrae | 1 | 2024 | 614 | 0.040 |
Why?
|
Plasmids | 1 | 2024 | 2273 | 0.040 |
Why?
|
Acyltransferases | 1 | 2021 | 305 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 5 | 2019 | 20680 | 0.040 |
Why?
|
Labial Frenum | 1 | 2019 | 6 | 0.040 |
Why?
|
Carcinoma | 1 | 2010 | 2312 | 0.040 |
Why?
|
Hydrocephalus | 1 | 2006 | 766 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15398 | 0.040 |
Why?
|
Glucose | 3 | 2019 | 4332 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1731 | 0.040 |
Why?
|
Endoscopy | 2 | 2023 | 1852 | 0.040 |
Why?
|
Pregnancy Complications | 1 | 2012 | 2970 | 0.040 |
Why?
|
Molecular Chaperones | 1 | 2022 | 761 | 0.040 |
Why?
|
Homozygote | 1 | 2022 | 1774 | 0.040 |
Why?
|
Age Factors | 2 | 2020 | 18380 | 0.040 |
Why?
|
Gene Deletion | 1 | 2024 | 2667 | 0.030 |
Why?
|
Mammals | 1 | 2022 | 1125 | 0.030 |
Why?
|
Risk Factors | 2 | 2024 | 74853 | 0.030 |
Why?
|
Benchmarking | 1 | 2023 | 1054 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11888 | 0.030 |
Why?
|
Incidence | 1 | 2015 | 21501 | 0.030 |
Why?
|
Antigens, Polyomavirus Transforming | 1 | 2017 | 255 | 0.030 |
Why?
|
Diagnosis, Differential | 3 | 2022 | 12966 | 0.030 |
Why?
|
Prevalence | 2 | 2024 | 15832 | 0.030 |
Why?
|
Trans-Activators | 1 | 2005 | 2849 | 0.030 |
Why?
|
Glucose Tolerance Test | 1 | 2019 | 1180 | 0.030 |
Why?
|
Lysosomes | 1 | 2021 | 932 | 0.030 |
Why?
|
Diabetes Insipidus | 1 | 2016 | 143 | 0.030 |
Why?
|
Gynecomastia | 1 | 2016 | 87 | 0.030 |
Why?
|
Sex Factors | 2 | 2020 | 10607 | 0.030 |
Why?
|
HEK293 Cells | 1 | 2024 | 4255 | 0.030 |
Why?
|
Skull | 1 | 2019 | 814 | 0.030 |
Why?
|
Brain | 2 | 2021 | 27178 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2020 | 1187 | 0.030 |
Why?
|
RNA Interference | 1 | 2022 | 2827 | 0.030 |
Why?
|
Drosophila melanogaster | 1 | 2022 | 1721 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2022 | 3418 | 0.030 |
Why?
|
Piperidines | 1 | 2002 | 1662 | 0.030 |
Why?
|
Heterozygote | 1 | 2020 | 2795 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9520 | 0.030 |
Why?
|
14-alpha Demethylase Inhibitors | 1 | 2012 | 4 | 0.030 |
Why?
|
Proteome | 1 | 2022 | 1898 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 11855 | 0.020 |
Why?
|
Ketoconazole | 1 | 2012 | 93 | 0.020 |
Why?
|
Gene Transfer Techniques | 1 | 2017 | 1216 | 0.020 |
Why?
|
Telomerase | 1 | 2017 | 749 | 0.020 |
Why?
|
Term Birth | 1 | 2012 | 140 | 0.020 |
Why?
|
Abruptio Placentae | 1 | 2012 | 116 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4018 | 0.020 |
Why?
|
Homeostasis | 1 | 2021 | 3335 | 0.020 |
Why?
|
Heart Rate | 1 | 2002 | 4202 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 612 | 0.020 |
Why?
|
Gonadotropins | 1 | 2011 | 240 | 0.020 |
Why?
|
Survival Analysis | 1 | 2002 | 10087 | 0.020 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2018 | 2027 | 0.020 |
Why?
|
Recovery of Function | 1 | 2019 | 2965 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 2924 | 0.020 |
Why?
|
Nerve Compression Syndromes | 1 | 2009 | 159 | 0.020 |
Why?
|
Gene Expression | 2 | 2016 | 7581 | 0.020 |
Why?
|
Child, Preschool | 2 | 2023 | 42478 | 0.020 |
Why?
|
Proteins | 1 | 2002 | 5996 | 0.020 |
Why?
|
Visual Field Tests | 1 | 2009 | 413 | 0.020 |
Why?
|
Abortion, Spontaneous | 1 | 2012 | 535 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4779 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2016 | 2132 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2012 | 3585 | 0.020 |
Why?
|
Risk Assessment | 1 | 2008 | 24278 | 0.020 |
Why?
|
Blood Pressure | 1 | 2002 | 8532 | 0.020 |
Why?
|
Cyclic GMP | 1 | 2007 | 394 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2002 | 3834 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 2844 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10570 | 0.020 |
Why?
|
Transcription Factors | 1 | 2024 | 12122 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3435 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2018 | 7119 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 1959 | 0.010 |
Why?
|
Immunotherapy | 1 | 2020 | 4752 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2011 | 2863 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13613 | 0.010 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 1642 | 0.010 |
Why?
|
Keto Acids | 1 | 2002 | 32 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5747 | 0.010 |
Why?
|
Labetalol | 1 | 2002 | 29 | 0.010 |
Why?
|
Secretory Vesicles | 1 | 2003 | 127 | 0.010 |
Why?
|
Phosphorylation | 1 | 2012 | 8278 | 0.010 |
Why?
|
Paraneoplastic Syndromes | 1 | 2003 | 154 | 0.010 |
Why?
|
Nitrous Oxide | 1 | 2002 | 166 | 0.010 |
Why?
|
Leucine | 1 | 2002 | 546 | 0.010 |
Why?
|
Hedgehog Proteins | 1 | 2005 | 772 | 0.010 |
Why?
|
DNA Methylation | 1 | 2014 | 4424 | 0.010 |
Why?
|
Aging | 1 | 2019 | 8731 | 0.010 |
Why?
|
Cause of Death | 1 | 2011 | 3710 | 0.010 |
Why?
|
Karyotyping | 1 | 2002 | 1176 | 0.010 |
Why?
|
Drainage | 1 | 2006 | 1179 | 0.010 |
Why?
|
Glutamine | 1 | 2002 | 575 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2003 | 2546 | 0.010 |
Why?
|
Isoflurane | 1 | 2002 | 384 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2007 | 2143 | 0.010 |
Why?
|
Gene Amplification | 1 | 2002 | 1089 | 0.010 |
Why?
|
Linear Models | 1 | 2007 | 5873 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2007 | 3228 | 0.010 |
Why?
|
Anesthetics, Inhalation | 1 | 2002 | 572 | 0.010 |
Why?
|
Survival Rate | 1 | 2011 | 12821 | 0.010 |
Why?
|
Rats | 1 | 2012 | 23707 | 0.010 |
Why?
|
Amino Acids | 1 | 2002 | 1709 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2005 | 2817 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2002 | 2511 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2007 | 4350 | 0.010 |
Why?
|
Respiration | 1 | 2002 | 1652 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2007 | 3851 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4562 | 0.010 |
Why?
|
Body Composition | 1 | 2002 | 2441 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2002 | 2033 | 0.010 |
Why?
|
Pregnancy | 1 | 2012 | 30215 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2005 | 11205 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 17063 | 0.000 |
Why?
|
Membrane Proteins | 1 | 2005 | 7846 | 0.000 |
Why?
|
Insulin Resistance | 1 | 2002 | 3987 | 0.000 |
Why?
|